Summary: The authors present 5-year follow-up data from the CAMMS223 study, reporting on the long-term safety and efficacy of alemtuzumab treatment compared with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). Over 5 years, alemtuzumab lowered the risk of sustained accumulation of disability by 72%. The annualised relapse rate over the 5 years was 0.11 for alemtuzumab and 0.35 for IFNβ-1a.
Most commonly occurring serious side effects were serious infections occurring in 7% of alemtuzumab treated patients, with 30% developing thyroid problems (compared to only 4% in IFNβ-1a group).
The study shows good evidence for the efficacy in reducing progression of disability and relapse rate reduction in patients with RRMS compared with IFNβ-1a and side effect profile in line with previously published data....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307